• Users Online: 30247
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Browse Articles Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2015  |  Volume : 6  |  Issue : 1  |  Page : 89

Trend in prevalence of hepatitis C virus infection among ß-thalassemia major patients: 10 years of experience in Iran

1 Department of Hematology/Oncology, Guilan University of Medical Sciences, Rasht, Iran
2 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; Department of Neurobiology, Care Science and Society (NVS), H1, Division of Family Medicine, Karolinska Institutet, Sweden, Sweden
3 Guilan Road Trauma Research Center, Guilan University of Medical Sciences, Rasht, Iran
4 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

Date of Submission25-Aug-2014
Date of Acceptance13-Apr-2015
Date of Web Publication08-Sep-2015

Correspondence Address:
Ali Davoudi-Kiakalayeh
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran
Login to access the Email id

Source of Support: We would like to thank the Guilan blood transfusion organization for financial support of this study, Conflict of Interest: None

DOI: 10.4103/2008-7802.164832

Rights and Permissions

Background: Hepatitis C virus (HCV) is the leading cause of transfusion transmitted infections (TTIs) among patients with b-thalassemia major. A high prevalence of HCV was reported among these patients. The aim of this study is seeking the trend of the prevalence of HCV infection among the patients with b-thalassemia major in Guilan province, Northern Iran over a 10-year period.
Methods: A retrospective study was conducted on 1113 patients with b-thalassemia major in the Guilan province, northern Iran from 2002 to 2012, using multiple data sources. A blood sample was taken from each patient, and a questionnaire regarding demographic data and risk factors was completed for them. Enzyme-linked immunosorbent assay and recombinant immunoblot assay for HCV were performed in all cases. A stepwise forward logistic regression analysis was done.
Results: The prevalence of hepatitis C infection among b-thalassemia major patients was 13.6%. The risk of hepatitis C among b-thalassemia major patients was greater before screening program for HCV (odds ratio = 9.6, 95% confidence interval: 2.3-40.5). In addition, the prevalence of anti-HCV seropositivity was decreased dramatically among patients who have received transfusions after implementation of blood donor screening for HCV. There were no positive HCV cases in the patients younger than 10 years.
Conclusions: The risk of TTIs including HCV can be reduced by implementing screening program for healthy blood.

Keywords: Blood transfusion, hepatitis C, Iran, transfusion transmitted infections, b-thalassemia

How to cite this article:
Jafroodi M, Davoudi-Kiakalayeh A, Mohtasham-Amiri Z, Pourfathollah AA, Haghbin A. Trend in prevalence of hepatitis C virus infection among ß-thalassemia major patients: 10 years of experience in Iran. Int J Prev Med 2015;6:89

How to cite this URL:
Jafroodi M, Davoudi-Kiakalayeh A, Mohtasham-Amiri Z, Pourfathollah AA, Haghbin A. Trend in prevalence of hepatitis C virus infection among ß-thalassemia major patients: 10 years of experience in Iran. Int J Prev Med [serial online] 2015 [cited 2023 Oct 3];6:89. Available from: https://www.ijpvmjournal.net/text.asp?2015/6/1/89/164832

  Introduction Top

Patients with b-thalassemia major who regularly receive transfusions are at risk of developing posttransfusion hepatitis (PTH). Among these infections, hepatitis B and C are the most common. [1] It is well-known that hepatitis C virus (HCV) is a major cause of PTH infection, and it can lead to severe inflammation in liver with long-term problems such as disabling symptoms, cirrhosis, and hepatocellular carcinoma. [2] Due to lack of effective vaccine and inadequate infection control policies for HCV poses a significant and growing public health problem in low- and middle-income countries. [3]

According to the World Health Organization, 170 million of people are infected by HCV in the world. [2] Over 21.3 million of them live in the eastern Mediterranean region. [4] A lot of studies among multi-transfused thalassemia patients reported the prevalence of HCV in b-thalassemia patients at a wide range of 3-67.3%. [5, 6, 7, 8, 9] However, under and over reporting trends have also been identified in the intra and inter countries in this region. [10] Mean age, duration, and mean amount of blood transfused have been associated with an increased risk of HCV infection in b-thalassemia patients. Saber-Firoozi et al. stated that the relative risk of HCV infection for each unit of blood transfusion is about 0.2%. [11] Study on thalassemia patients who regularly receive blood transfusion, could reflect the safety of blood products indirectly.

Iran is located in the middle of, what is called "the thalassemia belt." Thalassemia is an important health problem throughout Iran, particularly in the Guilan province, northern Iran. There are 1120 patients with thalassemia major in the Guilan province, and most of them had received blood transfusion before 1996, when routine blood screening for HCV infection started. The recent studies in Iran have shown that the prevalence of HCV infection in b-thalassemia patients are different from 2% to 32%. [12,13] In one of these studies, a very high prevalence of HCV among thalassemic and hemodialysis patients in Rasht (capital of the Guilan province) was reported (64%). [14] Regarding the controversies on the true prevalence of HCV infections, the objective of this study was to determine the actual rate of HCV infection in b-thalassemia patients in the Guilan province, northern Iran, in order to identify factors associated with HCV infection. This information could be used to develop more effective prevention strategies.

  Methods Top

Study design

This cross-sectional study was conducted in the Guilan province, one of the highest prevalent regions of thalassemia in Iran (about 10% of whole thalassemia population), during 2002-2012. Guilan province is located in northern Iran bordering the Caspian Sea with a population of about 2.5 million residents. The following administrative were assessed; including the noncommunicable disease centers, health centers, hospital records and clinics of hematology. A multi-stage sampling technique was applied during the study period to select a large, representative sample of sex and age group from all administrative to minimize refusals. Using a predesigned questionnaire, demographic data such as, age, gender, duration of receiving blood transfusion, residency, were obtained. A total of 1113 thalassemia patients were enrolled in this study. Blood sample of those patients who were frequently attending thalassemia clinics, were tested after obtaining written consent.

Laboratory process

The 2 nd and 3 rd generations of the immunoenzymatic test were used to screen b-thalassemia major patients during the study period. Positive case is defined as a patient who initial and duplicated (ELISA) test was positive. Samples were tested in accordance with manufacturer's specifications in duplicate to determine the percentage that was repeatedly reactive, confirmed by recombinant immunobloting assay test.

Statistical analysis

Records from different administrative were merged into a single file, using Excel 2012. Records were then sorted for cases that were reported in sources, using multiple screenings. Data analyses were conducted using the SPSS (version 18) 18)(SPSS Inc., Shicago IL). The Chi-square test was conducted to analyze significant associations between patient's characteristics and HCV positivity. A two-tailed P < 0.05 was considered as statistically significant. Variables history of blood transfusion and death were entered as predictors in a logistic regression model to calculate the adjusted odds ratio (OR) and 95% confidence interval where HCV seropositivity was the dependent variable.

This study proposal was reviewed, approved and sponsored by the Guilan Blood Transfusion Center and reviewed and approved by the Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.

  Results Top

During the study period from March 2002 (5 years after HCV screening) to March 2012, the data of 1113 b-thalassemia major patients were enrolled. These data also include the new cases (7%, 78 cases) and the number of patients that who died (3.3%, 36 cases) during the observation period. Of total cases, 48.1% were males and 51.9% were females, with female to male ratio 1.08:1. Mean age (±standard deviation [SD]) was 22.93 ± 8.37 years (range from 1 to 52 years). The age group 21-30 years, which included 522 (47%) of the cases was the largest group and the age group over the 40 years, which included 29 the (2.6%) of the cases was the smallest group. Demographic features are presented in [Table 1].
Table 1: Demographic characteristics of thalassemia patients in Guilan province during study period

Click here to view

Among 1113 thalassemia cases, 152 were found to be positive for anti-HCV, given an overall prevalence of HCV of 13.6%. The risk for being HCV positive was 1.5 time higher among males than females. The mean age (±SD) of positive cases was higher than that of negative cases (26.11 ± 5.3 vs. 22.5 ± 8.5). This study showed that prevalence of hepatitis C was found to be 12% in the age group less than 20, and almost 68% in the age group of 20-30 years, 20.5% in the age group of 30-40 and 0.01% in the age group of more than 40 years respectively, and the difference was statistically significant. However, there were no positive HCV cases in the patients younger than 10 years. This study also showed that there was no significant difference risk of infection according to blood groups [Table 2].
Table 2: Univariate association between potential risk factors and HCV seropositivity

Click here to view

History of blood transfusion is main risk factors associated with anti-HCV seropositivity in our study population and had a significant univariate association with HCV seropositivity (P < 0.0001) [Table 2]. All 14.2% of positive anti-HCV cases have had a history of blood transfusion.

The majority of HCV positive patients have already received more than 150 times blood transfusion [Figure 1].
Figure 1: Number of blood transfusion status with thalassemia patients and HCV positive cases

Click here to view

The multiple logistic regression test for variables gender, age group, blood group and history of blood transfusion demonstrated that, there is a strong significant relationship between history of blood transfusions with HCV infection before routine screening (1995), where the risk of blood transfusion before 1995 (OR 9.6, P = 0.003) with seropositivity of hepatitis C were predominant.

  Discussion Top

The current study shows that transfusion transmitted infections have always been a problem in thalassemia patients in last decade. The prevalence of HCV infection among patients with b-thalassemia major in our study (13.6%) was less than the reported rates in many other low- and middle-income countries. [5, 6, 7, 8, 9, 10] The HCV prevalence among high-risk patients in other reports varies from 3% to 67.3% and similar results were found when looking at the rates in different parts of Iran, which ranged from 5.1% to 64%. [13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23] This discrepancy suggests that other factors are contributing to the relatively low rates of HCV infection in our study. One possible factor could be, using different laboratory tests with a wide range of validity for detecting HCV. Many reports were based on only ELISA tests without complementary and confirmation tests. However, some of those have used polymerase chain reaction as a confirmation test.

The second factor is that the prevalence of HCV infection in the general population in Iran is very low (<1%). [10]

The third factor is the policies that implement by blood transfusion organization, about screening of blood regarding the blood safety. In Iran, routine screening for blood borne diseases has been mainly conducted among blood and tissue donors since the 1996, and it seems that this policy reduced infection rate since that time. Furthermore, implementation of tests for screening of blood donors after 1995 in Iran has leaded to almost complete absence of any new HCV infected patients in the group age of <10 years of old. Also, the rate of infection in patients of 10-15 years old, who were at the beginning of this blood screening program was very low. This shows the importance of the blood donors screening program.

We think that previously reported high prevalence of HCV infection among high-risk patients (63.8%) in the Guilan province [14] has some bias including inappropriate sample size and unreliable laboratory tests.

Our study had a number of limitations. Because of the lack of information and missing data in records of patients, risk factors such as drug abuse, tattooing, and high-risk behaviors were not assessed in this study.

  Conclusions Top

This study shows that blood donors screening program in regarding providing safe blood for the recipient was successful and prevent the risk of HCV infection among thalassemia patients. Finally, electronic data recording system for early detection of any infection in thalassemia patients is recommended.

  Acknowledgements Top

We would like to thank the Guilan blood transfusion organization for the financial support of this study. We also appreciate helps of personnel of noncommunicable diseases unit of health centers of the Guilan province.

  References Top

El-Faramawy AA, El-Rashidy OF, Tawfik PH, Hussein GH. Transfusion transmitted hepatitis: Where do we stand now? A one center study in upper Egypt. Hepat Mon 2012;12:286-91.  Back to cited text no. 1
Ataei B, Hashemipour M, Kassaian N, Hassannejad R, Nokhodian Z, Adibi P. Prevalence of anti HCV infection in patients with Beta-thalassemia in Isfahan-Iran. Int J Prev Med 2012;3:S118-23.  Back to cited text no. 2
Rezvan H, Abolghassemi H, Kafiabad SA. Transfusion-transmitted infections among multitransfused patients in Iran: A review. Transfus Med 2007;17:425-33.  Back to cited text no. 3
Ramia S, Eid-Fares J. Distribution of hepatitis C virus genotypes in the Middle East. Int J Infect Dis 2006;10:272-7.  Back to cited text no. 4
Vidja PJ, Vachhani JH, Sheikh SS, Santwani PM. Blood transfusion transmitted infections in multiple blood transfused patients of Beta thalassaemia. Indian J Hematol Blood Transfus 2011;27:65-9.  Back to cited text no. 5
Ali I, Siddique L, Rehman LU, Khan NU, Iqbal A, Munir I, et al. Prevalence of HCV among the high risk groups in Khyber Pakhtunkhwa. Virol J 2011;8:296.  Back to cited text no. 6
Wanachiwanawin W, Luengrojanakul P, Sirangkapracha P, Leowattana W, Fucharoen S. Prevalence and clinical significance of hepatitis C virus infection in Thai patients with thalassemia. Int J Hematol 2003;78:374-8.  Back to cited text no. 7
Al-Kubaisy WA, Al-Naib KT, Habib M. Seroprevalence of hepatitis C virus specific antibodies among Iraqi children with thalassaemia. East Mediterr Health J 2006;12:204-10.  Back to cited text no. 8
López L, López P, Arago A, Rodríguez I, López J, Lima E, et al. Risk factors for hepatitis B and C in multi-transfused patients in Uruguay. J Clin Virol 2005;34 Suppl 2:S69-74.  Back to cited text no. 9
Alavian SM, Tabatabaei SV, Lankarani KB. Epidemiology of HCV Infection among Thalassemia patients in eastern mediterranean countries: A quantitative review of literature. Iran Red Crescent Med J 2010;12:365-76.  Back to cited text no. 10
Saberi-Firoozi M, Yazdankhah S, Karbasi HT. Anti-HCV seropositivity among multiply-transfused patients with thalassemia major in southern, Iran. Irn J Med Sci 1996;21:59.  Back to cited text no. 11
Alavian S, Adibi P, Zali M. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med 2005;8:84-90.  Back to cited text no. 12
Samimi-Rad K, Shahbaz B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia 2007;13:156-63.  Back to cited text no. 13
Ansar MM, Kooloobandi A. Prevalence of HCV infection in thalassemia and hemodialysis patients in north Iran-Rasht. J Viral Hepat 2002;9:390-2.  Back to cited text no. 14
Tamaddoni A, Mohammadzadeh I, Ziaei O. Seroprevalence of HCV antibody among patients with beta-thalassemia major in Amirkola Thalassemia Center, Iran. Iran J Allergy Asthma Immunol 2007;6:41.  Back to cited text no. 15
Kabir A, Alavian SM, Keyvani H. Distribution of hepatitis C virus genotypes in patients infected by different sources and its correlation with clinical and virological parameters: A preliminary study. Comp Hepatol 2006;5:4.  Back to cited text no. 16
Jafroodi M, Asadi R. Prevalence of HCV in Thalassemia Major Patients in Guilan Province, Iran. Presented in: The 4 th Congress of Iranian Pediatric Hematology, Oncology Society, Kerman, Iran; 2006.  Back to cited text no. 17
Ghafourian M, Zadegan MA, Zandian K, Haghirizadeh M. Prevalence of hepatitis C virus (HCV) among thalassemia patients in Khuzestan province, south west Iran. Pak J Med Sci 2009;25:113-7.  Back to cited text no. 18
Torghabeh HM, Badiei Z. Transfusion transmitted viruses in individuals with b thalassemia major at Northeastern Iran, a retrospective sero-epidemiological survey. Iran J Blood Cancer 2008;1:1-4.  Back to cited text no. 19
Ansari H, Kamani H, Sajro A. Prevalence of hepatitis C and related factors among beta thalassemia major patients in southern Iran in 2005-2006. J Med Sci 2007;7:997-1002.  Back to cited text no. 20
Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B. Epidemiology of HBV, HCV and HIV in patients with beta thalassemia in Iran: A multicenter study. Arch Iran Med 2006;9:319-23.  Back to cited text no. 21
Karimi M, Ghavanini AA. Seroprevalence of hepatitis B, hepatitis C and human immunodeficiency virus antibodies among multitransfused thalassaemic children in Shiraz, Iran. J Paediatr Child Health 2001;37:564-6.  Back to cited text no. 22
Hassanshahi G, Arababadi MK, Assar S, Hakimi H, Karimabad MN, Abedinzadeh M, et al. Post-transfusion-transmitted hepatitis C virus infection: A study on thalassemia and hemodialysis patients in southeastern Iran. Arch Virol 2011;156:1111-5.  Back to cited text no. 23


  [Figure 1]

  [Table 1], [Table 2]

This article has been cited by
1 Global burden and unmet needs in the treatment of transfusion-dependent -thalassemia
Gian Luca Forni, Giuliano Grazzini, Jeanne Boudreaux, Vanessa Agostini, Laurel Omert
Frontiers in Hematology. 2023; 2
[Pubmed] | [DOI]
2 Abnormal glucose homeostasis in patients of HbE-thalassemia: Prevalence and possible pathogenesis using the Oxford HOMA model
Ankita Sen, Pranab Kumar Sahana, Prantar Chakrabarti, Pramit Ghosh, Tuphan Kanti Dolai, Rajib De
Journal of Hematology and Allied Sciences. 2022; 0: 1
[Pubmed] | [DOI]
3 Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study
Fahimeh Safarnezhad Tameshkel, Mohammad Hadi Karbalaie Niya, Bahare Amirkalali, Nima Motamed, Jamshid Vafaeimanesh, Mansooreh Maadi, Masodreza sohrabi, Amir Hossein Faraji, Mahmoodreza Khoonsari, Hossein Ajdarkosh, Mehdi Nikkhah, Elham Sobrakhshankhah, Farhad Zamani
Archives of Medical Research. 2022;
[Pubmed] | [DOI]
4 Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategies
Meisam Moghimbeygi,Seyed Moayed Alavian
Journal of Virus Eradication. 2020; 6(3): 100006
[Pubmed] | [DOI]
5 Hepatitis C Virus Treatment in Children: A Challenge for Hepatitis C Virus Elimination
Manal H. El-Sayed,Giuseppe Indolfi
Seminars in Liver Disease. 2020; 40(03): 213
[Pubmed] | [DOI]
6 Identifying genotype profile of chronic hepatitis C infection in Southwest Iran
Hassan Khadempour-Arani,Ali Shojaeian,Ameneh Mehri-Ghahfarrokhi,HadiRaeisi Shahraki,Abbas Karimi,Alireza Dehghan,GholamReza Mobini
Journal of Research in Medical Sciences. 2020; 25(1): 85
[Pubmed] | [DOI]
7 Prevalence of Transfusion Transmissible Infections in Beta-Thalassemia Major Patients in Pakistan: A Systemic Review
Hamid Ehsan,Ahsan Wahab,Faiz Anwer,Raheel Iftikhar,Muhammad N Yousaf
Cureus. 2020;
[Pubmed] | [DOI]
8 Safety of allogeneic hematopoietic stem cell transplantation in beta-thalassemia patients with chronic hepatitis C infections treated at a pediatric center
Archana Ramgopal,Adam Lauko,Seth Rotz,Rabi Hanna
Pediatric Transplantation. 2019; : e13520
[Pubmed] | [DOI]
9 Blood transfusion therapy for -thalassemia major and hemoglobin E -thalassemia: Adequacy, trends, and determinants in Sri Lanka
Sachith Mettananda,Hashan Pathiraja,Ravindu Peiris,Nethmi Wickramarathne,Dayananda Bandara,Udaya de Silva,Chamila Mettananda,Anuja Premawardhena
Pediatric Blood & Cancer. 2019; : e27643
[Pubmed] | [DOI]
10 Seroprevalence and geographical distribution of hepatitis C virus in Iranian patients with thalassemia: a systematic review and meta-analysis
Amir Shamshirian,Reza Alizadeh-Navaei,Ali Akbar Pourfathollah,Reza Alipoor,Ali Reza Mohseni
Journal of Laboratory Medicine. 2019; 0(0)
[Pubmed] | [DOI]
11 Hepatitis C virus prevalence among patients with thalassemia and inherited bleeding disorders in Iran: a systematic review and meta-analysis
Vahideh Takhviji,Ebrahim Azizi,Ali Kordian,Abbas Khosravi,Mostafa Paridar,Mohammad Ali Jalalifar,Omid Kiani Ghalehsardi,Mohammad Abdollahi,Mofid Hosseinzadeh,Zahra Bakshandeh
Hematology & Transfusion International Journal. 2018; 6(5)
[Pubmed] | [DOI]
12 The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis
Masoud Behzadifar,Hassan Abolghasem Gorji,Nicola Luigi Bragazzi
Archives of Virology. 2018;
[Pubmed] | [DOI]
13 The Effectiveness of Sofosbuvir and Daclatasvir in the Treatment of Hepatitis C in Thalassaemia Major Patients and their Effect on Haematological Factors
Farhad Zamani,Hossein Ajdarkosh,Fahimeh Safarnezhad-Tameshkel,Azita Azarkeivan,Hossein Keyvani,Farshad Naserifar,Jamshid Vafaeimanesh
Indian Journal of Medical Microbiology. 2018; 36(2): 224
[Pubmed] | [DOI]
14 Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta-thalassemia major: Occult HCV infection
Roya Kahyesh-Esfandiary,Zohreh-Azita Sadigh,Maryam Esghaei,Mohammad-Navid Bastani,Tahereh Donyavi,Alireza Najafi,Atousa Fakhim,Farah Bokharaei-Salim
Journal of Medical Virology. 2018;
[Pubmed] | [DOI]
15 Acute changes in cardiac function by direct acting antiviral therapy for hepatitis C-infected patients with thalassemia
Arezoo Khosravi,Hamidreza Karimi-Sari,Mahdi Abedi-Andani,Bita Behnava,Ali Namvar,Ali Anvar,Seyed Moayed Alavian
Journal of Medical Virology. 2018;
[Pubmed] | [DOI]
16 Prevalence of Sero-Molecular Markers of Hepatitis C and B Viruses among Patients with -Thalassemia Major in Northern West Bank, Palestine
Kamal Dumaidi,Amer Al-Jawabreh,Fekri Samarah,Maha Rabayaa
Canadian Journal of Infectious Diseases and Medical Microbiology. 2018; 2018: 1
[Pubmed] | [DOI]
17 Efficacy and Side Effects of Sofosbuvir and Daclatasvir for Treatment of Hepatitis C in Thalassemia Major Patients on Interferon-Based Regimens
Jamshid Vafaeimanesh,Fahimeh Safarnezhad Tameshkel,Hossein Ajdarkosh,Azita Azarkeyvani,Mahmoodreza Khoonsari,Amirhossein Faraji,Masoudreza Sohrabi,Sima Aten,Hossein Keyvani,Farhad Zamani
Hepatitis Monthly. 2018; In Press(In Press)
[Pubmed] | [DOI]
18 Prevalence of Hepatitis C Virus Antibodies among Beta-Thalassemia Major Patients in Kurdistan Province, Iran
Silan Mohammadi,Mazaher Khodabandehloo
Archives of Clinical Infectious Diseases. 2017; In Press(In Press)
[Pubmed] | [DOI]
19 Generic Direct Acting Antivirals in Treatment of Chronic Hepatitis C Infection in Patients of Thalassemia Major
Aabha Nagral,Smita Sawant,Nishtha Nagral,Pathik Parikh,Priya Malde,Rashid Merchant
Journal of Clinical and Experimental Hepatology. 2017; 7(3): 172
[Pubmed] | [DOI]
20 The Prevalence of Hepatitis C Virus Infection in Patients With Thalassemia in Zabol City of Iran
Maysam Yousefi,Mohammad Moein Dehesh,Mehrnoosh Ebadi,Azizallah Dehghan
International Journal of Infection. 2016; In Press(In Press)
[Pubmed] | [DOI]
21 Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major
Mohammad-Navid Bastani,Farah Bokharaei-Salim,Hossein Keyvani,Maryam Esghaei,Seyed Hamidreza Monavari,Mojtaba Ebrahimi,Saba Garshasebi,Shahin Fakhim
Archives of Virology. 2016;
[Pubmed] | [DOI]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article
Article Figures
Article Tables

 Article Access Statistics
    PDF Downloaded334    
    Comments [Add]    
    Cited by others 21    

Recommend this journal